Prime Medicine, Inc. (PRME) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
10/31
1.6 / 5 stars
All 31 Win/Lose results and 89 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 4 wins, 6 losses, 2 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LosePRME / S&P 6.03% / 15.20% |
No dataPRME / S&P / 15.00% |
LosePRME / S&P -30.77% / 50.40% |
| 2026-Q11/2 |
WinPRME / S&P 0.29% / -4.33% |
No dataPRME / S&P / 11.30% |
LosePRME / S&P -22.36% / 27.70% |
| 2025-Q41/3 |
LosePRME / S&P -37.36% / 2.65% |
WinPRME / S&P 55.28% / 9.00% |
LosePRME / S&P -16.97% / 13.40% |
| 2025-Q32/3 |
WinPRME / S&P 124.29% / 8.12% |
WinPRME / S&P 647.13% / 4.61% |
LosePRME / S&P -30.10% / 13.45% |
| 2025-Q22/3 |
WinPRME / S&P 24.12% / 10.94% |
WinPRME / S&P 739.42% / 4.83% |
LosePRME / S&P -28.11% / 10.63% |
| 2025-Q11/3 |
LosePRME / S&P -31.85% / -4.27% |
WinPRME / S&P 550.76% / 4.98% |
LosePRME / S&P -26.15% / 10.57% |
| 2024-Q40/2 |
LosePRME / S&P -24.55% / 2.41% |
No dataPRME / S&P / 5.25% |
LosePRME / S&P -24.31% / 6.15% |
| 2024-Q31/2 |
LosePRME / S&P -24.71% / 5.89% |
No dataPRME / S&P / 5.89% |
WinPRME / S&P 178.38% / 6.11% |
| 2024-Q21/2 |
LosePRME / S&P -26.57% / 4.28% |
No dataPRME / S&P / 5.38% |
WinPRME / S&P 20.56% / 5.12% |
| 2024-Q10/2 |
LosePRME / S&P -20.99% / 10.56% |
No dataPRME / S&P / 5.71% |
LosePRME / S&P -29.45% / 5.59% |
| 2023-Q40/2 |
LosePRME / S&P -7.13% / 11.69% |
No dataPRME / S&P / 6.81% |
LosePRME / S&P -48.46% / 7.78% |
| 2023-Q30/2 |
LosePRME / S&P -34.88% / -3.27% |
No dataPRME / S&P / 7.52% |
LosePRME / S&P -92.13% / -5.03% |
| 2023-Q21/2 |
WinPRME / S&P 19.11% / 8.74% |
No dataPRME / S&P / 9.50% |
LosePRME / S&P -80.67% / -8.57% |
| 2023-Q10/1 |
LosePRME / S&P -33.80% / 7.50% |
No dataPRME / S&P / 10.77% |
No dataPRME / S&P / -15.69% |
| 2022-Q40/0 |
No dataPRME / S&P / 7.56% |
No dataPRME / S&P / 11.88% |
No dataPRME / S&P / -17.99% |
| 2022-Q30/0 |
No dataPRME / S&P / -4.88% |
No dataPRME / S&P / 13.47% |
No dataPRME / S&P / -1.41% |
| 2022-Q20/0 |
No dataPRME / S&P / -16.10% |
No dataPRME / S&P / 13.71% |
No dataPRME / S&P / 11.04% |
| 2022-Q10/0 |
No dataPRME / S&P / -4.60% |
No dataPRME / S&P / 15.97% |
No dataPRME / S&P / 42.23% |
| 2021-Q40/0 |
No dataPRME / S&P / 11.03% |
No dataPRME / S&P / 15.00% |
No dataPRME / S&P / 96.40% |
| 2021-Q30/0 |
No dataPRME / S&P / 0.58% |
No dataPRME / S&P / 10.77% |
No dataPRME / S&P / 69.42% |
| 2021-Q20/0 |
No dataPRME / S&P / 8.55% |
No dataPRME / S&P / 6.58% |
No dataPRME / S&P / 51.81% |
| 2021-Q10/0 |
No dataPRME / S&P / 6.17% |
No dataPRME / S&P / -1.06% |
No dataPRME / S&P / 7.39% |
| 2020-Q40/0 |
No dataPRME / S&P / 12.15% |
No dataPRME / S&P / -3.72% |
No dataPRME / S&P / -33.42% |
| 2020-Q30/0 |
No dataPRME / S&P / 8.93% |
No dataPRME / S&P / -2.04% |
No dataPRME / S&P / -27.10% |
| 2020-Q20/0 |
No dataPRME / S&P / 20.54% |
No dataPRME / S&P / -0.46% |
No dataPRME / S&P / -27.11% |
| 2020-Q10/0 |
No dataPRME / S&P / -19.60% |
No dataPRME / S&P / 3.47% |
No dataPRME / S&P / -14.75% |
| 2019-Q40/0 |
No dataPRME / S&P / 9.07% |
No dataPRME / S&P / 5.36% |
No dataPRME / S&P / 2.99% |
| 2019-Q30/0 |
No dataPRME / S&P / 1.70% |
No dataPRME / S&P / 5.02% |
No dataPRME / S&P / 0.21% |
| 2019-Q20/0 |
No dataPRME / S&P / 4.30% |
No dataPRME / S&P / 6.64% |
No dataPRME / S&P / 8.65% |
| 2019-Q10/0 |
No dataPRME / S&P / 13.65% |
No dataPRME / S&P / 8.12% |
No dataPRME / S&P / 14.29% |
| 2018-Q40/0 |
No dataPRME / S&P / -13.52% |
No dataPRME / S&P / 9.05% |
No dataPRME / S&P / 18.23% |
| 2018-Q30/0 |
No dataPRME / S&P / 7.71% |
No dataPRME / S&P / 10.21% |
No dataPRME / S&P / 19.06% |
| 2018-Q20/0 |
No dataPRME / S&P / 3.43% |
No dataPRME / S&P / 9.03% |
No dataPRME / S&P / 14.46% |
| 2018-Q10/0 |
No dataPRME / S&P / -0.76% |
No dataPRME / S&P / 7.68% |
No dataPRME / S&P / 12.46% |
| 2017-Q40/0 |
No dataPRME / S&P / 6.64% |
No dataPRME / S&P / 7.03% |
No dataPRME / S&P / 13.82% |
| 2017-Q30/0 |
No dataPRME / S&P / 4.48% |
No dataPRME / S&P / 5.68% |
No dataPRME / S&P / 17.57% |
| 2017-Q20/0 |
No dataPRME / S&P / 3.09% |
No dataPRME / S&P / 4.83% |
No dataPRME / S&P / 17.74% |
| 2017-Q10/0 |
No dataPRME / S&P / 6.07% |
No dataPRME / S&P / 3.67% |
No dataPRME / S&P / 13.32% |
| 2016-Q40/0 |
No dataPRME / S&P / 3.82% |
No dataPRME / S&P / 2.09% |
No dataPRME / S&P / 7.05% |
| 2016-Q30/0 |
No dataPRME / S&P / 3.85% |
No dataPRME / S&P / 0.20% |
No dataPRME / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 12.35% | 20.78% |
| Annualized return | 12.35% | 20.78% |
5Y · 2022-10-20 to 2026-08-27
| Metric | PRME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.32% | 83.14% |
| Annualized return | -25.03% | 12.86% |
10Y · 2022-10-20 to 2026-08-27
| Metric | PRME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.32% | 319.30% |
| Annualized return | -13.41% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |